“Users have long desired a small, discreet, and fully featured in-the-ear hearing aid. Through our innovative RightFit™ ...

NanoPalm’s technology is differentiated by its AI-assisted design and modular architecture, enabling tunable surface properties and selective cellular uptake. Originally developed for gene therapy ...

Valneva recorded an operating loss of €16.8 million in the first half of 2025 compared to an operating profit of €46.7 million in the first half of 2024. The decrease was mainly the result of the PRV ...

Chemotherapy and radiation therapy remain standard for locally advanced and metastatic cervical cancer. However, they often ...

Photo: Esteworld Opens Its First Representative Office in the UK in London ...

Europe is home to the majority of Sandoz operations, and this partnership is expected to meet nearly 90% of current electricity demand across the company’s European sites. Under the agreement, Sandoz ...

Valneva retransmettra aujourd’hui en direct la conférence téléphonique sur les résultats financiers du premier semestre 2025 à 15h00 CEST (9h00 EDT). Cette retransmission sera disponible sur le site ...

Claritas NucMed Technologies Ltd, a subsidiary of Claritas HealthTech Ltd, is based in London, United Kingdom, and is the authorised distributor of Claritas iPET™, iPETcertum™, iSPECTcardiac™, and ...

Männedorf, Switzerland, August 12, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today announced its financial results for the first half of 2025 and confirmed its outlook for full year 2025.

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Ianalumab, ...

The notes will be general unsecured, senior obligations of Ligand and will accrue interest payable semiannually in arrears on April 1 and October 1 of each year, beginning on April 1, 2026 at a rate ...

During the fireside chat, Drs. Campagna and Nikodem will highlight recent corporate updates, progress on lanifibranor and the Phase III NATiV3 trial in MASH and discuss the Company’s broader R&D ...